Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

被引：0
|
作者：
Gupta, Vikas
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason R.
DiPersio, John F.
Catalano, John V.
Deininger, Michael W. N.
Miller, Carole Brennan
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie Huling
Arcasoy, Murat.
Hexner, Elizabeth O.
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Kornacki, Deanna
Sun, Kang
Kantarjian, Hagop M.
机构：
[1] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mayo Clin, Scottsdale, AZ USA
[4] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[5] Washington Univ, Sch Med, St Louis, MO 63110 USA
[6] Frankston Hosp, Frankston, Australia
[7] Dept Clin Haematol, Frankston, Australia
[8] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[9] St Agnes Canc Inst, Baltimore, MD USA
[10] Weill Cornell Med Ctr, New York, NY USA
[11] Univ Michigan, Ann Arbor, MI 48109 USA
[12] Emory Univ, Sch Med, Atlanta, GA 30322 USA
[13] Birmingham Hematol Oncol Associates, Birmingham, AL USA
[14] Duke Univ, Hlth Syst, Durham, NC USA
[15] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[16] Canc Care Ctr South Texas, US Oncol, San Antonio, TX USA
[17] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[18] Columbia Univ, Med Ctr, New York, NY USA
[19] Incyte Corp, Wilmington, DE USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7012
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    Harrison, C. N.
    Vannucchi, A. M.
    Kiladjian, J-J
    Al-Ali, H. K.
    Gisslinger, H.
    Knoops, L.
    Cervantes, F.
    Jones, M. M.
    Sun, K.
    McQuitty, M.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Barbui, T.
    LEUKEMIA, 2016, 30 (08) : 1701 - 1707
  • [22] Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)
    Cervantes, Francisco
    Kiladjian, Jean-Jacques
    Niederwieser, Dietger
    Sirulnik, Andres
    Stalbovskaya, Viktoriya
    McQuity, Mari
    Hunter, Deborah S.
    Levy, Richard S.
    Passamonti, Francesco
    Barbui, Tiziano
    Barosi, Giovanni
    Gisslinger, Heinz
    Vannucchi, Alessandro M.
    Knoops, Laurent
    Harrison, Claire N.
    BLOOD, 2012, 120 (21)
  • [23] Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    C N Harrison
    A M Vannucchi
    J-J Kiladjian
    H K Al-Ali
    H Gisslinger
    L Knoops
    F Cervantes
    M M Jones
    K Sun
    M McQuitty
    V Stalbovskaya
    P Gopalakrishna
    T Barbui
    Leukemia, 2017, 31 : 775 - 775
  • [24] Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study
    Passamonti, Francesco
    Palandri, Francesca
    Saydam, Guray
    Egyed, Miklos
    Callum, Jeannie
    Devos, Timothy
    Sivgin, Serdar
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    Zor, Evren
    Gilotti, Geralyn
    Zhang, Yifan
    Griesshammer, Martin
    BLOOD, 2020, 136
  • [25] Long-Term Effects of Ruxolitinib on Bone Marrow Morphology in Patients With Myelofibrosis and Comparison to Best Available Therapy
    Kvasnicka, Hans Michael
    Thiele, Juergen
    Bueso-Ramos, Carlos E.
    Sun, William
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S155 - S155
  • [26] Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
    Hans Michael Kvasnicka
    Jürgen Thiele
    Carlos E. Bueso-Ramos
    William Sun
    Jorge Cortes
    Hagop M. Kantarjian
    Srdan Verstovsek
    Journal of Hematology & Oncology, 11
  • [27] Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
    Kvasnicka, Hans Michael
    Thiele, Juergen
    Bueso-Ramos, Carlos E.
    Sun, William
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [28] The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
    Hijiya, Nobuko
    Maschan, Alexey
    Rizzari, Carmelo
    Shimada, Hiroyuki
    Dufour, Carlo
    Goto, Hiroaki
    Kang, Hyoung Jin
    Guinipero, Terri
    Karakas, Zeynep
    Bautista, Francisco
    Ducassou, Stephane
    Yoo, Keon Hee
    Zwaan, Christian Michel
    Millot, Frederic
    Patterson, Briana C.
    Samis, Jill
    Izquierdo, Miguel
    Titorenko, Ksenia
    Li, Sai
    Sosothikul, Darintr
    BLOOD ADVANCES, 2023, 7 (23) : 7279 - 7289
  • [29] Long-term outcomes in NANOM-FIM trial: 5-year analysis
    Kharlamov, A.
    Gabinsky, J.
    EUROPEAN HEART JOURNAL, 2015, 36 : 478 - 478
  • [30] LONG-TERM INTERVENTION EFFECTS ON BONE MARROW MORPHOLOGY IN MYELOFIBROSIS: PATIENTS TREATED WITH RUXOLITINIB AND BEST AVAILABLE THERAPY
    Kvasnicka, H.
    Thiele, J.
    Bueso-Ramos, C. E.
    Sung, W.
    Cortes, J.
    Kantarjian, H. M.
    Verstovsek, S.
    HAEMATOLOGICA, 2013, 98 : 249 - 249
12345